Saturday, March 28, 2015

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). The company also has a second drug candidate, Actimab-A, now in a […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

CombiMatrix sets bold three-year vision

CombiMatrix sets bold three-year vision

March 10, 2015 by · Leave a Comment 

Tweet Mark McDonough, president and CEO of CombiMatrix (NASDAQ:CBMX), has set a bold three-year vision for the clinical diagnostic lab company, which specializes in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. “We’d like to grow the company to a market cap of at least $125-million, with revenue north of $40-million in […]

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

March 3, 2015 by · Leave a Comment 

Tweet After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. “We are also in the early stages of developing our U.S. regulatory strategy to gain […]

In conversation with Steve Damon

In conversation with Steve Damon

February 24, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=F4gEY5O0EcU’]

Tweet As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible for executing several key partnerships with various pharmaceutical companies for Altea’s novel transdermal patch technology, bringing over $45-million of non-dilutive financing to Altea. Prior […]

Neovasc launching Reducer in Europe for RA

Neovasc launching Reducer in Europe for RA

February 17, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=LdK0CXdhgDo’]

Tweet Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. “Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors and our own sales […]

In conversation with David Giljohann

In conversation with David Giljohann

February 10, 2015 by · Leave a Comment 

Tweet As CEO of closely-held AuraSense Therapeutics, Dr. David Giljohann is one of the original inventors of the company’s technology for first-in-class therapies based on its proprietary spherical nucleic acid (SNA) platform. In fact, the technology is based on his graduate work at Northwestern University with advisor Chad Mirkin, one of the founders of AuraSense and […]

Dipexium advancing EU approval strategy for Locilex

Dipexium advancing EU approval strategy for Locilex

February 3, 2015 by · Leave a Comment 

Tweet With its Phase 3 program underway in the U.S., Dipexium (NASDAQ:DPRX) has begun the regulatory process with the European Medicines Agency (EMA) for its Locilex topical treatment for diabetic foot infections (DFI). “Our strategy is to seek approval for Locilex in Europe based solely on data from our U.S. clinical trials, without any need […]

In conversation with Allen Krantz

In conversation with Allen Krantz

January 27, 2015 by · Leave a Comment 

Tweet As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974, he was a member of the Faculty of Chemistry at the State University of New York at Stony Brook and from 1974 to 1981 […]

EndyMed expands sales effort in U.S.

EndyMed expands sales effort in U.S.

January 20, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=CbjeD3PpeX4′]

Tweet After five years of selling its skin rejuvenation devices to medical professionals through a distributor, EndyMed Medical (TASE:ENDY) has launched a U.S.-based direct sales operation through subsidiary, EndyMed USA. “During the second half of 2014, we expanded the sales force team to cover all major markets in the U.S. and significantly increased our U.S.-based […]

Next Page »

Email Newsletters with Constant Contact
Google+